European heart journal. Cardiovascular pharmacotherapy

Keyphrases

Publications

volume 10, number 3, 2024

Casper Binding, Paul F Blanche, Gregory Yoke Hong Lip, Anne-Lise Kamper, Christina J Y Lee, Laila Staerk, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Jonas Bjerring Olesen, Anders Nissen Bonde
Efficacy and safety of oral anticoagulants according to kidney function among patients with atrial fibrillation. European heart journal. Cardiovascular pharmacotherapy 10 (3) (2024)
Morten Würtz, Kevin Kris Warnakula Olesen, Deepak L Bhatt, Salim Yusuf, Eva Muehlhofer, John W Eikelboom, Michael Maeng
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy. European heart journal. Cardiovascular pharmacotherapy 10 (3) (2024)

volume 10, number 4, 2024

Markus Wallner, Mattia Emanuele Biber, Davide Stolfo, Gianfranco Sinagra, Lina Benson, Ulf Dahlström, Soffia Gudbjörnsdottir, Francesco Cosentino, Peter G M Mol, Giuseppe M C Rosano, Javed Butler, Marco Metra, Lars H Lund, Giulia Ferrannini, Gianluigi Savarese
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Ricardo Caballero, Ricardo Caballero, Juan Tamargo
News in cardiovascular pharmacotherapy from the ACC.24 Meeting. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Markus Wallner, Mattia Emanuele Biber, Davide Stolfo, Gianfranco Sinagra, Lina Benson, Ulf Dahlström, Soffia Gudbjörnsdottir, Francesco Cosentino, Peter G M Mol, Giuseppe M C Rosano, Javed Butler, Marco Metra, Lars H Lund, Giulia Ferrannini, Gianluigi Savarese
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Sophie E Thompson, Mahmood Ahmad
Letter to the editor in response to Chan et al. 2023. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Yihong Sun, Koji Hasegawa, Heinz Drexel
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes? European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Marieta P Theodorakopoulou, Maria-Eleni Alexandrou, Alexandros Tsitouridis, Vasileios Kamperidis, Eva Pella, Andrew Xanthopoulos, Antonios Ziakas, Filippos Triposkiadis, Vassilios Vassilikos, Aikaterini Papagianni, Pantelis A Sarafidis
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Yi-Hsin Chan, Lai-Chu See, Abigail Louise D Te
Reply to Letter to the Editor by Thompson et al. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Ricardo Caballero, Ricardo Caballero, Juan Tamargo
News in cardiovascular pharmacotherapy from the ACC.24 Meeting. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Shinya Ikeda, Yugo Yamashita, Koh Ono
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine? European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Aleksandra Paterek, Marta Załęska-Kocięcka, Mateusz Surzykiewicz, Zuzanna Wojdyńska, Przemysław Leszek, Michał Mączewski
Non-coding RNA therapeutics in the treatment of heart failure. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Yihong Sun, Koji Hasegawa, Heinz Drexel
Should pharmacotherapy targeting lipoprotein(a) be further expanded for patients with diabetes? European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Stefan Agewall
Special focus on the new anti-diabetic drugs. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Talip E Eroglu, Ruben Coronel, Patrick C Souverein
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Talip E Eroglu, Ruben Coronel, Patrick C Souverein
Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Mattia Galli, Renato Francesco Maria Scalise, Eliano Pio Navarese
De-escalation versus shortening of dual antiplatelet therapy. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Yi-Hsin Chan, Lai-Chu See, Abigail Louise D Te
Reply to Letter to the Editor by Thompson et al. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Konstantin A Krychtiuk, Guillaume Marquis-Gravel, Shannon Murphy, Karen P Alexander, Karen Chiswell, Jennifer B Green, Lawrence Alan Leiter, Renato D Lopes, Stefano Del Prato, William Schuyler Jones, John J V McMurray, Adrian F Hernandez, Christopher B Granger
Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Matthias Peter Hilty, Christoph Siebenmann, Peter Rasmussen, Stefanie Keiser, Andrea Müller, Carsten Lundby, Marco Maggiorini
Beta-adrenergic blockade increases pulmonary vascular resistance and causes exaggerated hypoxic pulmonary vasoconstriction at high altitude: a physiological study. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Markus Wallner, Mattia Emanuele Biber, Davide Stolfo, Gianfranco Sinagra, Lina Benson, Ulf Dahlström, Soffia Gudbjörnsdottir, Francesco Cosentino, Peter G M Mol, Giuseppe M C Rosano, Javed Butler, Marco Metra, Lars H Lund, Giulia Ferrannini, Gianluigi Savarese
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Renata Cífková
Hypertension in pregnancy-what's new in the 2023 ESH Guidelines for the management of arterial hypertension. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Jonas Pivoriunas, Nils Tore Vethe, Einar Husebye, Morten Wang Fagerland, Stein Bergan, Oscar Kristiansen, John Munkhaugen Prof, Elise Sverre
Validation of a novel direct method to determine reduced adherence to atorvastatin therapy. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Marieta P Theodorakopoulou, Maria-Eleni Alexandrou, Alexandros Tsitouridis, Vasileios Kamperidis, Eva Pella, Andrew Xanthopoulos, Antonios Ziakas, Filippos Triposkiadis, Vassilios Vassilikos, Aikaterini Papagianni, Pantelis A Sarafidis
Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Sophie E Thompson, Mahmood Ahmad
Letter to the editor in response to Chan et al. 2023. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)

volume 10, number 5, 2024

Francesco Bruno, Florian A Wenzl, Ovidio De Filippo, Simon Kraler, Federico Giacobbe, Marco Roffi, Olivier Müller, Lorenz Räber, Christian Templin, Gaetano Maria De Ferrari, Fabrizio D'Ascenzo, Thomas Felix Lüscher, null null
Safety and effectiveness of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the SPUM-ACS study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Stergios Soulaidopoulos, Dimitrios Terentes-Printzios, Nikolaos Ioakeimidis, Konstantinos P Tsioufis, Charalambos Vlachopoulos
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Talip E Eroglu, Ruben Coronel, Gunnar Hilmar Gislason
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Arina Anna Tamborska, Charles F Bray, Tobias Kurth
Re: Shahim et al., 2024 "Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction". European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Stefan Agewall
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Paul Michael Haller, Niema Kazem, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Dobromir Dobrev, Elisabetta Cerbai, Erik Lerkevang Grove, Juan Carlos Kaski, Basil S Lewis, Alexander Niessner, Bianca Rocca, Giuseppe M C Rosano, Gianluigi Savarese, Renate B Schnabel, Anne Grete Semb, Samuel Sossalla, Sven Wassmann, Patrick Sulzgruber
Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Kazunori Mushiake, Kazushige Kadota, Koh Ono, Takeshi Kimura
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Bahira Shahim, Hong Xu, Maria Eriksdotter
Reply to 'Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction'. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Alexandre Stephane Slater, Sophia Khattak, Mark R Thomas
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Alexandre Stephane Slater, Sophia Khattak, Mark R Thomas
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Talip E Eroglu, Ruben Coronel, Gunnar Hilmar Gislason
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Stergios Soulaidopoulos, Dimitrios Terentes-Printzios, Nikolaos Ioakeimidis, Konstantinos P Tsioufis, Charalambos Vlachopoulos
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Stefan Agewall
European Heart Journal-Cardiovascular Pharmacotherapy to become fully open access in 2025. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Eirinaios Tsiartas, Αndreas S Papazoglou
Proton pump inhibitors: seeking the golden ratio between gastroprotection and cardiovascular risk. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Stergios Soulaidopoulos, Dimitrios Terentes-Printzios, Nikolaos Ioakeimidis, Konstantinos P Tsioufis, Charalambos Vlachopoulos
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Alexandre Stephane Slater, Sophia Khattak, Mark R Thomas
GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Yuki Obayashi, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, Ryusuke Nishikawa, Kenji Ando, Satoru Suwa, Tsuyoshi Isawa, Hiroyuki Takenaka, Tetsuya Ishikawa, Hideo Tokuyama, Hiroki Sakamoto, Takanari Fujita, Mamoru Nanasato, Hideki Okayama, Tenjin Nishikura, Hidekuni Kirigaya, Koji Nishida, Koh Ono, Takeshi Kimura, null null
Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Kazunori Mushiake, Kazushige Kadota, Koh Ono, Takeshi Kimura
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Kazunori Mushiake, Kazushige Kadota, Koh Ono, Takeshi Kimura
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Talip E Eroglu, Ruben Coronel, Gunnar Hilmar Gislason
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Arvid Engström, Jonas Söderling, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Björn Pasternak, Peter Ueda
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)
Juan Tamargo
After 30 years, the first endothelin-receptor antagonist (Aprocitentan) is approved for the treatment of arterial hypertension. European heart journal. Cardiovascular pharmacotherapy 10 (5) (2024)